Securing Medicare coverage and launching our first TrueMRD Test are significant milestones for Veracyte and important steps in enabling access to our MRD testing platform,” said Marc Stapley, Veracyte ...

Natera said the Food and Drug Administration approved its Signatera CDx as a test for bladder cancer. The drug can be used as a companion diagnostic with adjuvant atezolizumab to treat muscle-invasive ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Bladder cancer is one of the most common, and most overlooked, cancers in the United States, impacting hundreds of thousands of families each year. This is a public health issue that touches families, ...

The Decipher Bladder test identifies aggressive bladder cancer, aiding in treatment decisions beyond initial clinical staging. Non-luminal tumors in NMIBC show higher upstaging rates to MIBC and ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

One company has a big early lead in blood tests that detect cancer returning in survivors.